EquiReason

EquiReason research coverage

GeneDx Holdings Corp. WGS

Healthcare · Diagnostics & Research

24quarters analysed
12SEC filings read
4segments identified
11institutional managers tracked

Segments it reports

The business segments GeneDx Holdings Corp. reports in its own SEC filings.

  • Gene Dx
  • All Other Segments

Product lines it reports

The product and service lines GeneDx Holdings Corp. breaks its revenue into.

  • Diagnostic Test Third Party Insurance
  • Diagnostic Test Institutional Customers
  • Product And Service Other
  • Diagnostic Test Self Pay

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements27
  • Quarterly metric series12
  • Business segments4
  • SEC filings12
  • Deals and transactions1
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks7
  • Estimate revisions11
  • GAAP vs non-GAAP reconciliation1
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Guidance changes1
  • Revenue series24
  • Margin series7
  • Cash flow series23
  • Earnings series24
  • Operating cash flow series24
  • Per-share seriesnot found

This page says how much of GeneDx Holdings Corp. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open WGS in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

GeneDx Holdings Corp. (WGS) — research coverage | EquiReason